Novo Nordisk, a leading pharmaceutical company, has recently collaborated with Form Health and 9amHealth to enhance the care provided to individuals seeking support for obesity management. These partnerships aim to offer patients a comprehensive approach to tackling obesity, including nutritional guidance, lifestyle support, and access to prescription medications such as Wegovy (semaglutide) and Saxenda (liraglutide).
Form Health, one of the selected providers, boasts a multidisciplinary care team comprising certified physicians, advanced practice providers, and registered dietitians with specialized training in obesity treatment. This team collaborates to create personalized treatment plans that encompass behavioral health, nutrition, physical activity, and medication management. Dr. Florencia Halperin, Form Health’s chief medical officer, emphasizes the importance of holistic care in addressing obesity and its associated cardiometabolic conditions, highlighting the need for more than just a prescription.
On the other hand, 9amHealth offers a virtual healthcare platform that provides medical evaluations, at-home lab testing, personalized nutrition guidance, ongoing support, and prescriptions for weight loss medications. Co-founder and COO, Paul Geevarghese, underscores the increasing demand for medical care among individuals with chronic conditions like obesity, signaling a shift towards proactive healthcare seeking behaviors and the need for seamless virtual healthcare experiences.
Wegovy, an FDA-approved medication for weight management, has seen significant developments since its initial approval in 2021. In addition to aiding adults with obesity in weight loss, Wegovy’s indications have expanded to include adolescents and the reduction of cardiovascular risk. Moreover, the recent accelerated approval for treating metabolic dysfunction-associated steatohepatitis (MASH) further underscores the drug’s potential in addressing complex health conditions.
Despite Wegovy’s list price of $1,349, Novo Nordisk ensures affordable access for patients through various insurance plans, with most commercial insurance holders having minimal co-pays. For self-paying individuals, NovoCare offers Wegovy at a discounted rate of $499 per month, emphasizing the company’s commitment to improving affordability and accessibility to crucial medications for obesity management.
The success of Wegovy and other semaglutide products like Ozempic and Rybelsus has propelled Novo Nordisk’s financial growth, with sales reaching impressive figures in recent years. As these medications gain popularity and clinical recognition, they have also attracted the attention of regulatory bodies like CMS, which aims to negotiate prices for these drugs to manage healthcare costs effectively.
Looking ahead, Novo Nordisk is anticipating FDA approval for an oral formulation of Wegovy, which could revolutionize the landscape of obesity treatment by providing a convenient daily dosing option for patients. The decision on this formulation is expected by December 2025, promising further advancements in obesity care and medication accessibility.
Key takeaways:
– Novo Nordisk’s collaboration with Form Health and 9amHealth aims to revolutionize obesity care by providing comprehensive support beyond medication prescriptions.
– Wegovy’s expanding indications and affordable access options underscore Novo Nordisk’s commitment to improving obesity management.
– The success of semaglutide products highlights the growing importance of innovative medications in addressing complex health conditions like obesity.
– Anticipated FDA approval for an oral formulation of Wegovy signifies ongoing advancements in obesity treatment options.
Tags: formulation
Read more on managedhealthcareexecutive.com